Severe Hypoglycemia Market

1. Severe Hypoglycemia Presented by- DelveInsight Business Research

3. What is Severe Hypoglycemia? The use of glucagon also has the potential to confer economic advantages and to free up health care resources by reducing the number of patients who have to be admitted to the hospital with severe hypoglycemia.

4. Currently, various glucagon kits are available in the market as the Glucagon Emergency Kit (Eli Lilly) and the GlucaGenHypokit (Novo Nordisk A/S), which can be administered by IM or SC injection. 1 mg dose of glucagon (reconstituted in 1 mL of sterile water) is recommended for adults and children over 25 kg in weight; half dose (0.5 mL) is recommended for children below 25 kg in weight or younger than 6–8 years. If the patient does not respond immediately after receiving glucagon, medical help should be sought, and IV glucose administered as soon as possible.

5. In September 2019, GvokeHypoPen (Xeris Pharmaceuticals) was approved by the US FDA for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. It is a ready-to-use, room-temperature-stable, liquid glucagon inside a single-use auto-injector pen in 2 pre-measured doses (0.5 mg and 1 mg) developed using XeriSol technology.

6. How Many Regions Are Covered? The US EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan

7. There is currently a lack of consensus regarding the threshold blood glucose levels that classify different stages of hypoglycemia. Existing thresholds for defining hypoglycemia are based on observations from clinical trial settings and may not apply to everyday practice.

8. KOL- Views To keep up with the market trends, we take KOLs and SME’s opinion working in Severe Hypoglycemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Severe Hypoglycemiamarket trend. This will support the clients in making informed business decisions by identifying the overall scenario of the market and the unmet needs.

9. What is the Severe HypoglycemiaReport Scope? • The report covers the descriptive overview of Severe Hypoglycemia , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies • Comprehensive insight has been provided into the Severe Hypoglycemia epidemiology and treatment in the 7MM • Additionally, an all-inclusive account of both the current and emerging therapies for Severe Hypoglycemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape • A detailed review of Severe Hypoglycemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Severe Hypoglycemia market

10. What are the Severe Hypoglycemia Market Report Highlights? • In the coming years, Severe Hypoglycemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market • The companies and academics are working to assess challenges and seek opportunities that could influence Severe Hypoglycemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition • Major players are involved in developing therapies for Severe Hypoglycemia . Launch of emerging therapies will significantly impact the Severe Hypoglycemia market • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Severe Hypoglycemia

11. info@delveinsight.com ybhardwaj@delveinsight.com +91-9650213330 Do You Have Any Question or Query? Please keep this slide for attribution

12. Thanks!